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Although Src-like adaptor proteins (SLAP-1 and SLAP-2) weremainly studied in lymphocytes, where they act as negative regulators
and provide fine control of receptor signaling, recently, several other functions of these proteins were discovered. In addition to
the well-characterized immunoregulatory functions, SLAP proteins appear to have an essential role in the pathogenesis of type I
hypersensitivity, osteoporosis, and numerous malignant diseases. Both adaptor proteins are expressed in a wide variety of tissues,
where they have mostly inhibitory effects on multiple intracellular signaling pathways. In this review, we summarize the diverse
effects of SLAP proteins.
1. Introduction
Signal transducing adaptor proteins are a group of intra-
cellular and transmembrane molecules which are crucial
supplementary factors of signaling pathways. They mediate
interactions between different molecules and contribute to
the formation of signaling complexes. Adaptor proteins lack
enzymatic activity and interaction domains enable them to
connect with other molecules (e.g., proteins, lipids). Src-
like adaptor protein 1 (SLAP-1) was cloned in a yeast two-
hybrid screen with the cytoplasmic domain of the receptor
tyrosine kinase ephrin type-A receptor 2 as decoy [1, 2]. SLAP
proteins are not identical in size; SLAP-1 (or often quoted
as SLAP) contains 276 amino acids while SLAP-2 consists
of 261 amino acids (Figure 1). SLAP-1 and SLAP-2 contain
common SH2-SH3 domains. SH2 domains allow proteins to
dock to phosphorylated tyrosine containing epitopes. SH3
domains bind to hydrophobic amino acid and proline rich
molecules. SH domains of SLAP-2 form continuous 𝛽-sheet
that stretches the modular domains [3].
SLAP proteins were named after Src family kinases
which have the same SH sequences. Src protein tyrosine
kinases (PTKs) are protooncogenes that play a role in cell
proliferation, survival, and morphology. Unlike Src PTKs,
SLAP molecules do not have tyrosine kinase domains.
In addition to the myristoylated amino-terminal and SH
domains, SLAP family members contain unique carboxy-
terminal sequences as well. SLAP-1 has a longer carboxy-
tail than SLAP-2, but the N-terminal is longer in SLAP-2.
Myristoylated part of the SLAP promotes the associationwith
membranes, while isoforms without the myristoylated N-
terminal are located in the nucleus (Figure 1). Human SLAP
is coded by a 64 kb intron of the thyroglobulin gene, on
chromosome 8q24.23 in the candidate territory for a recessive
demyelinating neuropathy. Sequence analysis could not find
any mutations suggesting that this gene is not responsible for
the disease [4]. Human SLA2 gene is located on 20q11.23 [1].
Human SLAP-1 and SLAP-2 molecules show sequence
homology similarly to mouse SLAP proteins. SH domains
are the most similar parts of the two SLAP molecules, in
which the sequence homology is 59%, while the N-terminals
are the most different parts; they have only 19% identity.
SLAP-2 has a shorter alternative splice variant, called SLAP-
2v. This isoform contains only 210 amino acids due to the
deletion of 50 bp from exon 6, which results an alternative
reading frame. The splicing variant molecule does not have
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Figure 1: The schematic structure of SLAP molecules. SLAP-1 and SLAP-2 contain unique carboxy-terminal sequences, common SH2-
SH3 domains and amino-terminals which exist in myristoylated and nonmyristoylated isoforms. SH2 domains help molecules to bind to
phosphorylated tyrosine containing epitopes. The SH3 domains connect the proline and hydrophobic amino acid containing molecules.
Table 1: The expression of SLAP proteins in different tissues and cell lines.
Tissue/organ Expressed molecule Reference Cell line Expressed molecule Reference
Blood SLAP-1, SLAP-2 [1, 2] BaF3 SLAP-1, SLAP-2 [5]
Bone marrow SLAP-1, SLAP-2 [9, 10] BJAB SLAP-2 [35]
Brain SLAP-1 [9] D011.10T SLAP-2 [5]
Colon SLAP-2 [10] EL4 SLAP-1 [9]
Heart SLAP-1, SLAP-2 [10] FLI-1 transformed erythroblasts SLAP-1 [8]
Kidney SLAP-1 [9] HeLa SLAP-1 [7]
Liver SLAP-1 [9] HL60 SLAP-1 [12]
Lung SLAP-1, SLAP-2 [9] Jurkat SLAP-1, SLAP-2 [7, 35]
Lymph nodes SLAP-1 [7] NB-4 SLAP-1 [12]
Pancreas SLAP-1 [10] NIH3T3 SLAP-1 [10]
Placenta SLAP-1, SLAP-2 [10] RBL-2H3 SLAP-1 [11]
Prostate SLAP-2 [10] U.937 SLAP-1 [12]
Skeletal muscle SLAP-1, SLAP-2 [9, 10]
Small intestine SLAP-1, SLAP-2 [10]
Skin SLAP-1, SLAP-2 [10]
Spleen SLAP-1, SLAP-2 [9, 10]
Thymus SLAP-1, SLAP-2 [29, 30]
any c-Cbl interacting site. The biological relevance of SLAP-
2v is yet unknown [5, 6]. Although expression of SLAP-1
and SLAP-2 mRNAs has been most extensively studied in
lymphocytes, they are also expressed by numerous human
and murine tissues and cell lines [1, 2, 7–12] (Table 1). Several
proteins have been reported to interact with SLAP-1 and
SLAP-2 [5, 8, 9, 13–15] (Figure 2). SLAPs are involved in a
broad range of cellular processes, for example, lymphocyte
development, neuronal excitotoxicity and platelet activation.
SLAP molecules may participate in several pathological
conditions of the immune system as well. In the present
review, we will discuss the role of both SLAP proteins in
different cell types and overview our current understanding
regarding their relevance in pathological conditions.
2. SLAP Proteins in Immune Cells
2.1. SLAP-1 in T Lymphocytes. SLAP proteins were exten-
sively investigated in lymphocytes where they are strongly
expressed. SLAP-1 is involved in the regulation of the TCR
signal transduction pathway. TCR consists of a ligand binding
𝛼𝛽 heterodimer and the CD3 complex that includes the 𝛾𝜀
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Figure 2: The interaction partners of SLAP-1 (pink) and SLAP-2 (green). Several proteins have been reported to interact with SLAP-1
molecule: c-Cbl, CD3 𝜁 chain, ECK, EpoR, Ig𝛼, LAT, Lck, PDGFR, SLP-76, Syk, v-abl, Vav (protooncogene vav), ZAP70, c-kit, Flt3, and
FLI. SLAP-2 interacts with c-Cbl, CD3 𝜁 chain, CSFR, and ZAP70.
and 𝛿𝜀 heterodimers and the 𝜁𝜁 homodimer. The expression
of the 𝜁-chains is about the 10% of the other subunits of the
TCR complex. SLAP-1 may interact with many molecules
involved in the TCR signal transduction (ZAP-70, Syk, LAT,
CD3 𝜁-chain, Vav, and Lck) through the SH2 domain [9, 16].
SLAP-1 reduces the production of IL-2 and the transcrip-
tion of NFATc1 and AP-1, thereafter functions as a negative
regulator of the TCR signaling; both SH2 and SH3 domains
are necessary for this effect. However, upon ionomycin or
PMA activation of lymphocytes, these inhibitory effects are
absent suggesting that SLAP-1 regulates the proximal part
of the TCR pathway [7]. SLAP may associate with the
N-terminal of the E3 ubiquitin ligase c-Cbl in a tyrosine
phosphorylation independent way [16]. The simultaneous
expression of SLAP-1 and c-Cbl promotes the ubiquitination
and degradation of the 𝜁-chain, consequently enhancing the
recycling and preventing the accumulation of the receptor
complexes [17]. By contrast, similarly to SLAP −/− lympho-
cytes, c-Cbl −/− lymphocytes overexpress the 𝜁-chain due
to its abolished degradation [18]. For successful operation,
SLAP-1 requires the phosphorylation of the cytoplasmic
domains of the TCR 𝜁-chains and the activation of Lck, but
not of ZAP70 [19]. It has been shown that the phosphorylated
proportion of the 𝜁-chains is slightly traceable in Lck −/−
lymphocytes [20, 21]. SLAP colocalizes with early endosomes
according to confocal microscopy images [7] (Figure 3). It
is noteworthy that downregulation of 𝜁-chain of T-cells has
been observed in many pathological conditions including
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), human immunodeficiency virus (HIV) infection, and
various cancers [22–28].
Thymic selection is essential in shaping the peripheral
T cell repertoire. The central role of SLAP in lymphocyte
development has been also described. The fate of the early
lymphocytes depends on the TCR-mediated signals: both too
strong and too week signals through the TCR lead to cell
death (during positive and negative selections, resp.). The
expression of SLAP is strictly regulated during the thymic
development of lymphocytes. It is expressed at low levels
in CD4− CD8− cells and at high levels in CD4+ CD8+
thymocytes. SLAP as a regulator of the TCR expression plays
a pivotal role in the downregulation of TCR complexes of
the developing lymphocytes. Enhanced positive selectionwas
observed in SLAP deficient mice. Moreover, the apoptosis
of ZAP70 −/− cells was inhibited in the absence of SLAP
[29]. It has been reported that the proline rich-sequence
(PRS) of CD3𝜀 act together with SLAP in the regulation
of TCR expression in CD4+ CD8+ thymocytes. CD3𝜀 PRS
deficient cells were unable to degrade the 𝜁-chain [30]. In
double positive thymocytes, the chains of the TCR complex
are constitutively ubiquitinated, but the ubiquitination is
absent in mature cells. It has been shown that CD3𝜀 PRS,
Lck, c-Cbl, and SLAP are required for the ubiquitination and
degradation of the 𝜁-chains. In the absence of ubiquitination,
both the lysosomal sequestration and degradation are failed,
and TCR chains are upregulated in CD4+ CD8+ lympho-
cytes. In addition, modified TCR complex ubiquitination
influences the formation of the immunological synapse and
alters the selection of the immature cells [31]. The lack
of SLAP increases the avidity of the TCR which leads to
the negative selection of antigen specific CD8+ cells. All
these data suggest that SLAP plays a major role in the TCR
repertoire configuration [32].
2.2. SLAP-1 in B Lymphocytes. SLAP is associated with c-Cbl
in B lymphocytes, leading to BCR recycling [33] (Figure 4).
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Figure 3: The role of SLAP in T lymphocytes.
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Figure 4: The role of SLAP in B lymphocytes.
SLAP deficiency increases the BCR levels of immature B cells
in HEL-specific MD4- transgenic mice, which is a frequently
used model to study naı¨ve B lymphocytes. In this model the
upregulated receptor complex levels lead to increased signal
transduction. SLAP deficient mice have an increased number
of splenic B cells, but the surface expression of BCR and
IgM of mature lymphocytes is decreased. Furthermore, the
activation induced calcium flux is diminished in SLAP KO B
cells. In virtue of the previous data SLAP regulates the level
of BCR s which is essential for the adequate development and
function of B cells [34].
2.3. SLAP-2 in T and B Lymphocytes. Similarly to SLAP-
1, SLAP-2 also has an effect on lymphocyte receptor sig-
nalization. SLAP-2 has a negative regulatory role on the
antigen receptor signaling of T and B lymphocytes. The
overexpression of SLAP-2 reduces the surface levels of CD3
[5]. The overexpression of SLAP-1 and SLAP-2 inhibits the
upregulation of CD69 after antigen receptor cross-linking.
CD69 is an inducible cell surface glycoprotein, upregulated
during lymphocyte activation. SLAP-2 suppresses the antigen
binding induced calcium influx in T (Jurkat) and B (BJAB)
cell lines. SLAP-2 reduces the CD69 expression in Jurkat
cells (61%) more significantly than in BJAB cells (28%).
Similarly to SLAP-1, SLAP-2 does not impair the ionomycin
and PMA induced signalization [35]. SLAP-2 is associated
with ubiquitin ligase c-Cbl similarly to SLAP-1, deletion of
the carboxy-terminal of SLAP-2 was reported to inhibit this
connection [35]. In activated Jurkat cells SLAP-2 binds to c-
Cbl, ZAP-70, and CD3 𝜁 in a phosphorylation independent
manner [1]. The coexpression of SLAP-2 and ZAP-70 or Syk
in T-cell lines lead to the degradation of both kinases. Thus,
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Figure 5: The role of SLAP-2 in monocytes/macrophages.
SLAP-2 induces the c-Cbl dependent degradation of tyrosine
kinases and downregulates CD3 expression.
2.4. SLAPMolecules inMonocytes and Dendritic Cells. SLAP-
2 is expressed in human monocytes and bone marrow cells
[1, 35], but not in CSF1 independent monocyte cell lines such
as RAW264.7 [5]. It was shown that SLAP-2 may bind to
both c-Fms and c-Cbl, and several domains of SLAP-2 are
involved in this interaction (Figure 5). The overexpression of
SLAP-2 inmurine bonemarrow reduced theM-CSF-induced
tyrosine phosphorylation [36]. SLAP-2 downregulates the c-
Fms signaling through a c-Cbl dependent internalization and
degradation of the CSF-1R, providing a negative feedback
of the M-CSF pathway [37]. In addition, c-Fms stimulation
induces the phosphorylation of the serine rich N-terminal
domain of the SLAP-2 by a JNK dependent pathway [36].
The activation-induced GM-CSFR downregulation is
attenuated in SLAP-1 and SLAP-2 deficient bone marrow
dendritic cells (BM-DC), which is associated with enhanced
MAP/Erk and Akt pathways upon GM-CSF stimulation.
The inhibited activation through GM-CSFR impairs the
bone marrow derived dendritic cell maturation. SLAP-1 and
SLAP-2 deficient BM-DC cells produce less IL-12 and TNF-
𝛼 upon lipopolysaccharide (LPS) stimulation and induce
significantly less IFN-𝛾 secretion of T-lymphocytes than the
wild type cells [38]. These data suggest that SLAP proteins
are necessary formonocyte and dendritic cell maturation and
activation.
2.5. SLAP Proteins in Mast Cells. SLAP has a prominent role
in the regulation of intracellular signal transduction in mast
cells. SLAP-specific small interfering RNAs inhibit the effect
of dexamethasone on the phosphorylation of PLC 𝛾, LAT,
Syk, and ERK [39]. Actinomycin D inhibits the transcription
of SLAP following dexamethason treatment, suggesting that
the upregulation for SLAP-1 upon glucocorticoid treatment
occurs at the transcriptional level. Glucocorticoid receptor
activation is required for the elevation of the SLAP transcrip-
tion [40]. SLAP-1 plays a role in the negative regulation of
antigen-stimulated mast cells as well. Upon antigen stimu-
lation of the RBL-2H3 mast cell line, elevated transcription
of the SLA gene and upregulation of the SLAP-1 (but not
SLAP-2) protein were reported. An increased amount of
SLAP-1 was detected after 60 minutes stimulation and it
reached the maximum after 2-3 hours. By contrast, after
silencing of SLAP, increased IL-3 and MCP-1 production was
detected. Knock-down of SLAP by using siRNA increases the
expression of Fc𝜀RI [39]. Thus, SLAP appears to be a crucial
regulator of mast cell function.
3. The Function of SLAP Molecules in
Other Cell Types
3.1. SLAP-1 in Osteoclasts. Osteoclasts play a fundamental
role in the pathogenesis of osteoporosis. Inhibiting the
development and activation of osteoclasts is currently the
gold standard therapeutic strategy in this disease. Although
today several antiosteoporotic drugs are widely used in
the clinical practice, the effect of these medications on
increasing bone density and strength is moderate. There is
an inverse correlation between both SLAP-1 and SLAP-2 and
the tartrate-resistant acid phosphatase (osteoclastogenesis
marker) mRNA expression. The level of osteoclast-specific
protein mRNAs (e.g., catepsin K and MMP-9) are elevated
in the SLAP-1 −/− preosteoclasts. SLAP-1 has an inhibitory
effect on the MAP kinase pathway which is initiated with the
binding of M-CSF to its receptor c-Fms. This receptor is a
tyrosine kinase transmembrane protein which accumulates
in lipid rafts where it associates with SLAP-1. The lack
of SLAP enhances osteoclastogenesis without changing the
resorptive function of the individual cells [41]. In addition,
SLAP-1 deficiency increases the apoptosis of the mature
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polykariotic osteoclasts without altering the viability of the
precursors. According to our current understanding, SLAP-1
has a regulatory effect on osteoclastogenesis and mature cell
survival through the M-CSF pathway [41].
3.2. SLAP Molecules in Platelets and Fibroblasts. SLAP-2 is
expressed in human platelets and may associate with Syk, c-
Cbl, and LAT. After its activation, SLAP-2 promotes Syk and
c-Cbl to approach their substrates. SLAP-2 inhibits glyco-
protein VI (GPVI) initiated signal transduction of platelets
through the connection with c-Cbl [42]. This inhibitory
effect on thrombocyte activation is similar to those described
previously in lymphocytes [1, 5].
SLAP may also associate with platelet derived growth
factor receptor (PDGFR) in NIH3T3 mouse embryonic
fibroblast cell line. Overexpression of SLAP in NIH3T3
cells inhibits PDGF-induced mitogenesis [43] suggesting
that SLAP is a negative regulator of growth factor initiated
signaling.
3.3. SLAP-1 in Neurons. Although in embryonic rat telen-
cephalon sections SLAP-1 mRNA is absent in migrating neu-
rons, it is highly and selectively expressed in neurons which
have reached their final location. SLAP-1 has a characteristic
expression pattern during the development of the cortex.
It is expressed mostly by deeper stratum cells especially
by pyramid cells. Pyramid cells are typically located in the
deeper layers of the cortex, and they have connection with
the subcortical areas. It is not yet clear whether SLAP-
1 plays a role in the axon guidance during development
but apparently has a remarkable expression. There is also
a possible interaction between SLAP-1 and EphA receptors
[44].
Western blot analysis and immunolabeling of rat brain
extract showed that SLAP-1 is located in the postsynaptic
membrane. SLAP-1 has an association with EphAs and
NMDARs have a connection with EphBs [44, 45]. EphB may
excite the enlistment of EphAs and promote the recruitment
of SLAP-1 and NMDARs. Despite the analogous localization,
SLAP-1 does not affect the baseline activity of NMDARs
through a Src-dependent stimulation of the receptors. SLAP-
1 may have a role in the negative feedback which regulates
the number of the NMDARs and prevent excitotoxicity. This
effect of SLAP-1 is based on the proteasomal degradation
of redundant NMDARs in neurons [46]. The described role
of SLAP in neurons seems to be essential for the adequate
neuronal functions.
4. SLAP in Pathological Conditions
4.1. The Role of SLAP in Rheumatoid Arthritis. Rheumatoid
arthritis (RA) is a common autoimmune disease that is
associated with progressive disability and systemic compli-
cations. Symmetric synovial inflammation of multiple joints,
especially the small joints of the hands and the feet, is
characteristic for the disease. The ongoing inflammation
leads to cartilage destruction, bone erosions, and subse-
quent joint deformities. Although the current treatment
strategy, especially the use of biologicals, improved largely
the outcome of the disease, still only a small portion of
the patients are in sustained remission and systemic com-
plications (including cardiovascular risk) still represent a
significant challenge. TNF-𝛼 plays an essential role in the
pathogenesis of RA through promotion of angiogenesis,
suppression of regulatory T-cell activation, and cytokine and
chemokine expression.
According to the recently published data of our research
group, TNF-𝛼 treatment downregulates the expression of 𝜁-
chain of CD4 T-lymphocytes reversibly and selectively in
a dose dependent way. Decreased 𝜁-chain expression leads
to the hyporesponsiveness of T-cells. TNF-𝛼 induces the
expression of SLAP which promotes the proteasomal but not
the lysosomal degradation of the 𝜁-chain. Silencing SLAP
with short interfering RNAs inhibits the TNF-𝛼 induced 𝜁-
chain degradation. TNF-𝛼 treatment does not alter the SLAP
mRNA level, suggesting that TNF-𝛼 controls SLAP activ-
ity through miRNA mediated posttranscriptional silencing.
CD4+ T-lymphocytes isolated from RA patients expressed
more than 2-fold higher SLAP levels than the T-cells of
healthy donors. TNF-𝛼 treatment enhances the expression
of SLAP in the CD4+ T-lymphocytes of healthy donors
and DMARD treated RA patients but does not alter the
expression of CD4+ T-cells isolated from biological DMARD
(etanercept, certolizumab pegol) treated patients [47].
A spontaneous mutation in ZAP70 protein uncoupled
proximal TCR signal transduction and led to severe sym-
metrical arthritis in SKG mice upon exposure to zymosan.
According to recently published data, SLAP deficiency
dramatically reduced both the incidence and severity of
zymosan-induced chronic autoimmune arthritis in SKGmice
[48]. The protective role of SLAP deficiency was associ-
ated with the increased number of regulatory T-cells and
decreased amount of Th17 cells [48].
4.2. The Role of SLAP in Malignant Diseases and in Ery-
thropoiesis. SLAP expression is increased in several cancers
including chronic myeloid leukemia (CML), chronic lym-
phocytic leukemia (CLL), and prostate cancer. By contrast,
its expression is decreased in acute myeloid leukemia (AML),
myeloma, and colon cancer [13]. Furthermore, SLAP is
associated with several oncogenic signaling pathways.
It was recently reported that the transmembrane pro-
tooncogene c-kit is degraded through a SLAP dependent
pathway. SLAP binds to the WT c-kit and initiates its ubiq-
uitylation and degradation in the proteasome. By contrast,
SLAP does not have a similar regulatory effect on the onco-
genic c-kit variant (c-kit D816V). Oncogenic c-kit associates
with SLAP and phosphorylates it on three different tyrosines
(Y120, Y258, and Y273); the phosphorylated forms of SLAP
do not alter the downstream signaling of the mutant c-Kit.
These data suggest that SLAP regulates WT c-kit signaling,
but the oncogenic variant escapes from this negative feedback
regulation [49].
The Fms like tyrosine kinase (Flt3) is a receptor tyrosine
kinase, which is predominantly expressed in hematopoietic
progenitor cells. SLAP associates with both the WT and
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mutated, oncogenic Flt3 (Flt3-ITD). Silencing of SLAP with
short interfering RNAs leads to an attenuated MAPK signal
pathway. After ligand stimulation, SLAP colocalizes with the
Flt3-ITD and targets it for c-Cbl dependent ubiquitylation
and proteasomal degradation. About 30% of patients with
AML have mutation in the Flt3 gene and gain of function
mutations contribute to the initiation ofAML.The expression
of SLAP is increased in patients with acute promyelocytic
leukemia (APL) carrying Flt3-ITD mutation as compared to
the Flt3-WT [13].
FLI-1 is a transcription factor, a member of the E26
transformation-specific (ETS) protein family. Furthermore,
the FLI-1 locus is an integration site for the Friend murine
leukemia virus, which induces erythroleukaemia in respon-
sive mice. SLAP protein and mRNA levels are overexpressed
in FLI-1 transformed erythroblasts [8]. SLAP binds to both
the phosphorylated and unphosphorylated forms of the ery-
thropoietin receptor (EpoR). SLAP expression prevents the
EPO-induced differentiation, whose effect is associated with
the inhibition of STAT5 activation and BCL-X upregulation.
Both STAT5 andBCL-X are critical in EPO-induced signaling
[8]. SLAP may mediate the erythropoiesis in this manner.
According to recently published data, SLAP is expressed
in colon epithelium, but it is significantly downregulated
in colorectal tumors [15]. Interestingly, silencing of SLAP
promotes tumor progression, while overexpression inhibits
tumor growth and invasiveness. SLAP promotes the desta-
bilization of the Src substrate ephrin type-A receptor 2
(EphA2) in the intestinal cells. EphA2 plays a critical role
in the regulation of several intracellular signal pathways
which mediate cell migration, invasion, and angiogenesis.
The inhibitory effect of SLAP appears to be independent from
c-Cbl but has an association with the ubiquitination factor
UBE4A and with the pTyr594-EphA2. These results suggest
a tumor-suppressive effect of SLAP in colorectal cancers
[15].
5. Conclusions and Future Perspectives
SLAP proteins are expressed in a variety of cell types which
indicates a conserved function of these proteins. Both SLAP-1
and SLAP-2 have a prominent role in the negative regulation
of several membrane bound receptors and receptor tyrosine
kinases, thereafter SLAPs play a central role in the regulation
of intracellular signal transduction and cell reactivity. The
proper function of SLAPs is necessary for immunoreceptor
repertoire configuration and helps to avoid uncontrolled cell
activation, proliferation, and migration. SLAP molecules are
involved in the ubiquitination of proteins, which may lead
to proteasomal degradation. Selective regulation of SLAP
molecules in different cell types may allow the fine control
of cell activation and differentiation. Exploring the precise
role of SLAP proteins will contribute to the understanding
of many yet unknown physiological regulatory processes.
In addition, tissue specific targeting of SLAP may provide
valuable therapeutic approaches in diverse diseases including
RA, osteoporosis, immunodeficiency, and different cancers.
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